Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Featured trial
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

nivolumab
cancer chemotherapy
lung carcinoma
squamous non-small cell lung cancer
advanced lung cancer
  • 543 views
  • 04 May, 2022
  • 143 locations
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. NIVO/IPI are monoclonal antibodies (mAbs) that inhibit the immune checkpoint proteins programmed death receptor-1 (PD-1

nivolumab
carcinoma
monoclonal antibodies
tyrosine
VEGFR2
  • 57 views
  • 15 Sep, 2020
  • 1 location
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker

cancer chemotherapy
advanced sarcoma
liposarcoma
apatinib
cancer
  • 0 views
  • 04 Jun, 2022
  • 1 location
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer (APP)

-negative breast cancer patients. Apatinib is a highly potent human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor that has been independently developed in China, and it

HER2
growth factor
breast adenocarcinoma
paclitaxel
adjuvant therapy
  • 6 views
  • 26 Mar, 2022
  • 1 location
A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR

growth factor
measurable disease
VEGFR2
solid tumour
kinase inhibitor
  • 4 views
  • 22 Mar, 2022
  • 1 location
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

several cancers. The investigator previously reported the promising antitumor efficacy of camrelizumab (PD-1 inhibitor) combined with apatinib (VEGFR2 inhibitor) as second-line, or later, therapy in

  • 0 views
  • 07 Oct, 2021
  • 1 location
Neoadjuvant Immunotherapy for Resectable Gastric Cancer

) of PD-1 antibody monotherapy or in combination with anti-angiogenesis VEGFR2-TKI apatinib ± S1 ± Oxaliplatin in neoadjuvant (preoperative) treatment of resectable locally advanced gastric cancer.

adjuvant therapy
endoscopy
VEGFR2
oxaliplatin
shr-1210
  • 13 views
  • 22 Apr, 2022
  • 1 location
Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (CHIPRO)

This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.

primary peritoneal carcinoma
cancer chemotherapy
recurrent ovarian cancer
neutrophil count
paclitaxel
  • 0 views
  • 09 Apr, 2022
  • 1 location
Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

measurable disease
international normalized ratio
neutrophil count
cancer chemotherapy
  • 95 views
  • 06 Apr, 2022
  • 1 location
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy

HER2
growth factor
progesterone
capecitabine
anthracyclines
  • 0 views
  • 30 Apr, 2022
  • 1 location